Takeda Execs Admitted To Actos Scheme, Relator Claims
Law360, New York (January 12, 2016, 4:46 PM EST) -- A former GlaxoSmithKline executive turned whistleblower told a Massachusetts federal court Monday that Takeda Pharmaceutical executives admitted to a kickback scheme for the diabetes drug Actos and that acknowledgement overrides Takeda's demand for proof of specific claims.
Opposing a motion to dismiss, former GSK director of patent life-cycle maximization Peter P. Lawton said that top-level Takeda executives told him during three job interviews in 2009 that they were paying off physicians to prescribe Actos to treat prediabetes, even though the drug hadn’t been approved for such use. Because the executives knew the specifics of the illegal scheme, Lawton said, individual claims...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!